The Grenoble-based medtech company reached its €1.6 million seed target, with the equity portion raised solely from individual investors. The round was marked by renewed support from existing backers, including Grenoble Angels, and the company’s first international investors. The influx of capital comes with additional non-dilutive bank financing. The company also welcomed two new board members as it prepares to enter the US market in 2026.
Twinsight Closes €1.6 Million Seed Round to Accelerate US Commercialization of FDA-cleared SurgiTwin™ 3D and Complete Development Work on SurgiTwin™ 4D.
4 min read Premium comments
FDA clearanceTwinsightSurgiTwin 3DSurgiTwin 4Dequity financingnon-dilutive bank loansBpifranceCaisse d'EpargneCredit Agricole Sud Rhone AlpesUS investors
GRENOBLE, France – July 17, 2026 – Twinsight, a French medical technology company specializing in orthopedic surgical planning software, today announced the completion of its seed fundraising round, raising a total of €1.6 million. The round marks a decisive step for Twinsight, positioning the company to build on its recent FDA 510(k) clearance for SurgiTwin™ 3D and establish a strong commercial foothold in the United States while finalizing the development of SurgiTwin™ 4D and securing FDA clearance for the new solution.
Renewed commitment from existing investors and a demonstration of trust from surgeons
The €1.6 million raised combines equity financing with non-dilutive bank loans, secured with the support of Bpifrance, Caisse d'Epargne, and Crédit Agricole Sud Rhône Alpes.
Notably, the equity portion of the round was raised exclusively from individual investors who believe in Twinsight's vision. The support of individual angel investors, including expert orthopedic surgeons, sends a strong signal that SurgiTwin™ 3D addresses a genuine, unmet need in the field. The round also marks a milestone for Twinsight's international growth strategy, with the arrival of US investors and LBAN (Luxembourg Business Angel Network), who have now joined Grenoble’s angel investors, Grenoble Angels, with Twinsight from the beginning.
“We are proud to count these expert surgeons among our investors,” said Twinsight CEO Mathieu Rimaud. “Their support, alongside the continued trust of our individual investors, sends a strong signal that SurgiTwin™ 3D already responds to a real market need. This funding is decisive for Twinsight: It will allow us to fully capitalize on our FDA clearance and take our technology to surgeons across the United States. 2026 will be the year we officially enter the US market. The funds raised will also support continued development towards clearance of the next version of our software: SurgiTwin™ 4D, which will bring our innovative biomechanical digital twin concept to the next level.”
"We are delighted to continue supporting Twinsight, a pioneering Grenoble-based medtech company as it advances medical research with its AI-enabled software solution, SurgiTwin™ 3D. It is particularly exciting to see the remarkable progress the team has made in addressing the U.S market. We are also proud to participate in this cross-border European financing round alongside LBAN – the Luxembourg Business Angel Network – also a member of the European Business Angels Network (EBAN). This investment reflects the value of cross-border collaboration in helping innovative European deeptech companies scale internationally," said Philippe Rase, President, Grenoble Angels and Co-President, France Angels.
Strengthening governance for the next stage of growth
In addition to the successful completion of this seed round, Twinsight also announced the appointment of two new members to its Board of Directors: Cyrille Fleury and David Anderson.
A recognized leader in the medical device industry, Cyrille Fleury brings more than twenty years of operational and strategic leadership experience. As former CEO of Groupe Menix, he drove strong growth, launched AI-driven innovations, and led international expansion—including the opening of a US subsidiary—culminating in the successful sale of SERF to Stryker. He also held senior leadership roles at Tornier and Wright Medical. Cyrille currently is the Chairman of Galmeon and sits on the boards of several healthcare companies and on the board of directors of SNITEM, the French national federation of medical technology industries.
A global marketing and business development executive in the medical device and biologics industry, David Anderson brings a consistent track record of growing revenues through the application of marketing fundamentals and effective leadership. He is recognized for strategic thinking from organization to product, and for creating value through M&As. "I'm honored to join the Twinsight Board of Directors," said Anderson. “Twinsight's digital twin technology has the potential to transform total knee replacement planning by enabling more personalized implant placement while enhancing surgical efficiency. The combination of clinical impact, technological innovation, and market opportunity makes this an exciting time to be part of the company's journey.”
Looking ahead to 2026
Building on its FDA 510(k) clearance obtained for SurgiTwin™ 3D in 2025, the influx of capital and the strategic insights of the two new board members will position Twinsight to build its network of experts and partners in the US to prepare for commercial ramp-up and boost revenue growth as SurgiTwin™ 3D reaches surgeons across the United States. The funds raised will also allow Twinsight to finalize development of SurgiTwin™ 4D and begin the FDA 510(k) clearance process—a decisive step toward broadening Twinsight’s solutions for the US market.
About Twinsight
Founded in 2020 and based in La Tronche (Grenoble), France, Twinsight is a medical technology company dedicated to developing innovative software solutions for orthopedic surgery planning. The company's mission is to provide surgeons with a dynamic digital twin of each patient to personalize and improve surgical care. Today, the company's groundbreaking SurgiTwin™ 3D is bringing unprecedented levels of precision to knee replacement surgery while saving precious operating room time. In the future, Twinsight intends to bring the power of personalized digital twins to joints other than the knee and introduce dynamic movement into its models to provide unprecedented 4D simulation. The company's solutions will make operating blind a thing of the past by giving surgeons actionable data designed to improve patient outcomes.
Twinsight's multidisciplinary team combines expertise in medical imaging, artificial intelligence, orthopedic surgery, and regulatory affairs to develop advanced technological solutions that address real-world clinical challenges.
Contact Information
Mathieu Rimaud
+33668020561
Why This Matters
Two Perspectives
MBA Lens: Economic and industry impact
Twinsight secured €1.6 million in seed funding, combining individual equity and non-dilutive bank loans, to accelerate US commercialization of its FDA-cleared SurgiTwin™ 3D orthopedic surgical planning software. The company plans US market entry in 2026, leveraging new board expertise for strategic growth and network building. This funding also supports development of SurgiTwin™ 4D, aiming to enhance personalized knee replacement planning and surgical efficiency.
- The funding supports a strategic US market entry in 2026 for SurgiTwin™ 3D, capitalizing on its FDA clearance.
- New board members with extensive medical device and global marketing experience will guide US expansion and competitive positioning.
PhD Lens: Clinical and outcomes impact
Twinsight completed a €1.6 million seed round to advance its orthopedic surgical planning software. SurgiTwin™ 3D, an AI-enabled solution, provides a dynamic digital twin for personalized knee replacement implant placement, having received FDA 510(k) clearance in 2025. The funding will also finalize development of SurgiTwin™ 4D, which aims to incorporate dynamic movement for advanced 4D simulation, enhancing surgical precision and patient outcomes.
- SurgiTwin™ 3D utilizes AI to create patient-specific digital twins for precise knee replacement planning, cleared by FDA 510(k).
- Future development of SurgiTwin™ 4D will integrate dynamic movement into models, aiming to provide advanced biomechanical simulation for improved surgical outcomes.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.